Skip to main content
森萱医药 logo

森萱医药 — Investor Relations & Filings

Ticker · 920946 Beijing Stock Exchange Manufacturing
Open in API
Filings indexed 417 across all filing types
Latest filing 2023-04-27 Board/Management Inform…
Country CN China
Listing Beijing Stock Exchange 920946

About 森萱医药

https://www.senxuan.cn/

Jiangsu Senxuan Pharmaceutical Co., Ltd. specializes in the research, development, and production of pharmaceutical intermediates, active pharmaceutical ingredients (APIs), and specialized fine chemicals. The company’s product portfolio includes key intermediates for antiviral medications, such as those used in the treatment of HIV, and anticonvulsant agents like Primidone. Additionally, it produces high-purity chemical solvents including 1,4-dioxane and 1,3-dioxolane for diverse industrial applications. Senxuan Pharmaceutical maintains a focus on advanced chemical synthesis and large-scale manufacturing capabilities, adhering to international quality standards to support the global life sciences and chemical sectors. Its operations are characterized by a commitment to technical innovation and the supply of critical chemical building blocks for complex therapeutic formulations.

Recent filings

Filing Released Lang Actions
第三届董事会第二十次会议决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of the resolutions passed at the 20th meeting of the 3rd Board of Directors of Jiangsu Senxuan Pharmaceutical Co., Ltd. It includes details about the meeting's time, place, attendance, and the voting results on the agenda item, which is the approval of the 2023 first quarter report. The document references the actual quarterly report being disclosed separately on the Beijing Stock Exchange information platform (announcement number 2023-039). The document itself does not contain the financial data or the report but is an announcement of the board meeting resolutions. Therefore, it fits the category of Board/Management Information (MANG) as it relates to board meeting decisions and management announcements rather than the report itself or a regulatory filing.
2023-04-27 Chinese
2023年一季度报告
Interim / Quarterly Report Classification · 100% confidence The document is titled as a "2023 First Quarter Report" for Jiangsu Senxuan Pharmaceutical Co., Ltd. It contains detailed financial data for the first quarter of 2023, including balance sheet, income statement, cash flow statement, and explanations of significant changes in financial data. It also includes shareholder information and disclosures about major events and commitments. The document is comprehensive and covers a period shorter than a full fiscal year (quarterly). It is not an announcement or a brief summary but a full quarterly financial report with substantive financial data and analysis. Therefore, it fits the definition of an Interim / Quarterly Report (IR). Q1 2023
2023-04-27 Chinese
2022年年度股东大会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is titled as a "2022 年年度股东大会决议公告" which translates to "2022 Annual General Meeting Resolution Announcement." It details the date, location, attendance, and voting results of the 2022 Annual General Meeting (AGM) of Jiangsu Senxuan Pharmaceutical Co., Ltd. The document includes resolutions passed at the AGM, voting percentages, and references to other reports disclosed elsewhere. It is a formal announcement of the AGM resolutions and voting outcomes rather than the full AGM materials or presentations. The document length is about 6,581 characters, which is consistent with an announcement rather than a full report. Therefore, the document fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA).
2023-04-27 Chinese
投资者关系活动记录表
Investor Presentation Classification · 95% confidence The document is an investor relations activity record for a performance explanation meeting related to the 2022 annual report. It includes Q&A about the company's quarterly report release, business outlook, cash flow, and development plans. The document is short (1866 characters) and mainly records the event and investor questions rather than providing full financial statements or detailed analysis. It references the upcoming quarterly report release and the annual report but does not contain the reports themselves. Therefore, it is not an Annual Report (10-K) or Interim Report (IR). It is also not a Call Transcript (CT) since it is a record of an investor meeting rather than a conference call transcript. The document fits best as an Investor Presentation (IP) or AGM Information (AGM-R) since it is a performance explanation meeting related to the annual report. Given it is a performance explanation meeting (业绩说明会), which is typically an investor presentation event, the best classification is Investor Presentation (IP). Confidence is high due to clear indicators of the document type and content.
2023-04-26 Chinese
2022年年度报告说明会预告公告
AGM Information Classification · 95% confidence The document is a notice announcing a scheduled annual report explanation meeting (说明会) for the 2022 annual report of 江苏森萱医药股份有限公司. It references the 2022 annual report that was previously disclosed (公告编号：2023-013) and provides details about the meeting time, location, participants, and how investors can join and submit questions. The document itself does not contain the annual report or financial data but is an announcement about the meeting to discuss the annual report. The document length is short (1138 characters) and fits the pattern of a report publication announcement or meeting notice rather than the full annual report. Therefore, according to the rules, this is classified as AGM Information (AGM-R) because it is related to the annual report meeting presentation and materials sharing event, not the report itself or a regulatory filing.
2023-04-20 Chinese
2022年年度权益分派预案公告
Notice of Dividend Amount Classification · 95% confidence The document is titled as a 2022 annual equity distribution plan announcement by Jiangsu Senxuan Pharmaceutical Co., Ltd. It discusses the proposed dividend payout based on the audited 2022 annual report, including details on the dividend per share, total dividend amount, and the approval process involving the board and shareholders. The document is an announcement of the dividend distribution plan (equity distribution plan) and includes information about the board's approval and the upcoming shareholder meeting for final approval. It does not contain the full annual report or financial statements but rather focuses on the dividend proposal and related procedural details. The document length is about 2061 characters, which is relatively short and consistent with an announcement rather than a full report. Therefore, this document fits the category of Notice of Dividend Amount (DIV).
2023-03-28 Chinese

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.